CAMP4 THERAPEUTICS CORPORATION (CAMP)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
CAMP Files Annual Report to Shareholders
Based on the document provided, the actual content of the ARS (Annual Report to Shareholders) for Camp4 Therapeutics Corp is not visible in the text. The document appears to be a placeholder or index entry. However, I can explain what an ARS filing typically contains and what it means for you as an
SEC filings
All filings →Insider trades
All insider trades →CAMP4 THERAPEUTICS CORPORATION has no reported insider trades in the last 90 days.